MAPLE GROVE, Minn. – Upsher-Smith announced the launch of KYMBEE (deflazacort) Tablets, indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Manufactured by Upsher-Smith in Minnesota, KYMBEE is the only deflazacort backed by Upsher-Smith’s Promise of Support Program.
Available in 6 mg, 18 mg, 30 mg, and 36 mg strengths, KYMBEE Tablets are dispensed through Orsini Specialty Pharmacy, a leader in rare disease and complex therapy solutions.
“At Upsher-Smith, we recognize the challenges associated with accessing certain medications for DMD and the stress this can create for families,” said Michelle Zachman, Medical Affairs Director, Upsher-Smith. “Through the availability of KYMBEE and our Promise of Support Program, we’re proud to offer a U.S.-manufactured product, backed by our comprehensive support program designed to help ease some of the challenges associated with prescribing and accessing deflazacort.”
Upsher-Smith’s Promise of Support Program for KYMBEE
KYMBEE is backed by the Upsher-Smith Promise of Support Program, designed to assist families throughout their treatment journey. The comprehensive program provides:
- Copay assistance
- Help navigating insurance coverage
- Pathways to access therapy, even when insurance challenges arise
- A dedicated support team
%20Tablets){kind=link}